Group Work Recommendations- what to start Group WHAT 1.

Slides:

Advertisements

Similar presentations

Challenges to Pediatric Antiretroviral Treatment Elaine Abrams, David Hoos MTCT-Plus.

Advertisements

ART in HIV-Infected Patients with TB: Research Priorities Group II Facilitator: David Cohn Rapporteur: Soumya Swaminathan.

TB/HIV Research Priorities: TB Preventive Therapy.

Group Work Recommendations-When to Start Group C.

WHO Guidelines and future perspectives for treatment monitoring Nathan Ford Dept of HIV/AIDS World Health Organization.

Starting children and infants on ART; what do the guidelines say? Dr Siobhan Crowley Paediatric & Family HIV Care Department of HIV/AIDS World Heath Organization,

Improving Retention, Adherence, and Psychosocial Support within PMTCT Services: Implementation Workshop for Health Workers All slide illustrations by Petra.

Objective of the DAP A) Specify an analysis plan that can be applied to a wide variety of clinical HIV resistance studies. B) Include both Intervention.

P1060 commentary Philippa Musoke MBChB Makerere University –Johns Hopkins University Research Collaboration, Kampala Uganda.

Country Experience Informing Feasibility Option B+ (Malawi) Tenofovir phase in 1 st line( Zambia) d4T phase out in HIV programmes Raising CD4 threshold.

WHO Guidelines for treatment monitoring Nathan Ford Dept of HIV/AIDS World Health Organization.

Critical issues for Adults with HIV: Presentation of Systematic reviews and Main recommendations WHO 2013 ARV Guidelines Launch Dr. Meg Doherty, WHO, Geneva.

Raltegravir for the prevention of mother-to-child transmission of HIV MJ Trahan, V Lamarre, ME Metras, N Lapointe, F Kakkar Centre Hospitalier Universitaire.

HIV Treatment and Care Research priorities Facilitator – Dr Saphonn Vonthanak 12 participants 29 agreed topics –not grouped on methodology or subject category.

Draft WHO Pediatric ARV Guidelines Revision Summary 10/23/05 Lynne M. Mofenson, M.D. Pediatric, Adolescent and Maternal AIDS Branch National Institute.

Future ART options for HIV-infected children exposed to maternal HAART Lee Kleynhans Experts Roundtable June 2008.

THE NEVEREST STUDY AT RAHIMA MOOSA MCH Ashraf Coovadia Adjunct Professor Enhancing Childhood HIV Outcomes (Wits Paediatric HIV Clinics) Rahima Moosa Mother.

The Strategic Use of ARVs | IAC Satellite, July 22, |1 | Strategic Use of Antiretroviral Drugs WHO Perspective for Future Guidelines Chair of WHO.

Antiretroviral Postexposure Prophylaxis after Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV in the United States Recommendations.

1 HIV/AIDS Related Research Agenda Workshop Phnom Penh, Sunway Hotel March 28-29, 2007.

2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.

When to Initiate ART in Adults and Adolescents (2009 WHO Guidelines) Target PopulationClinical conditionRecommendation Asymptomatic Individuals (including.

1 Advantages and risks for a child to be exposed to the triple prophylaxis during pregnancy and breastfeeding What is the best for the child ? Pr C. Courpotin.

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection DR. S.K CHATURVEDI DR. KANUPRIYA CHATURVEDI.

UK-CAB Jan05 BHIVA treatment guidelines UK-CAB - 28 Jan 2005 Simon Collins, HIV i-Base.

Concept Sheet Development: Developing the Question Kara Wools-Kaloustian M.D. M.S.

Indications for Initiation of ARV Therapy in Children Age >1 Year Clinical Category CD4 + Cell Percentage Plasma HIV RNA Copy Number Recommendation AIDS.

Human Resource Constraints and Roll out of more efficacious regimens for PMTCT The Zambian experience Nande Putta MD MPH Technical Assistant PMTCT & Paediatric.

EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.

WHO PMTCT ARV Guidelines 2012 Programmatic Update EFV During Pregnancy Nathan Shaffer PMTCT Technical Lead, WHO IATT Webinar 11 July, 2012.

Group Work Recommendations Testing Group Members-names.

8èmes Rencontres Nord-Sud Avelin Aghokeng IRD-UMI233 & University of Montpellier I Yaoundé-Cameroon Avelin Aghokeng IRD-UMI233 & University of Montpellier.

Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.

ANTEPARTUM CARE. Pregnant Women Who Are ARV Naive (1)  Pregnant women with HIV infection should receive standard clinical, immunologic, and virologic.

Treatments, Current & Future Jon Cohen Science Magazine.

Prevention of Mother to Child Transmission Antiretroviral Drugs to Prevent MTCT.

Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.

HAIVN Harvard Medical School AIDS Initiative in Vietnam

Human Immune Deficiency Virus Infection Dr Huda Taha Sep 2015.

2 3 Population : 6,934,169 inhabitants 6 Sanitary regions UNAIDS (2014) - HIV prevalence : 2.5% = 110,000 PLHIV - Higher prevalence in southern regions.

First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.

WHO 2013 Consultative Meeting Tawanna Hotel October 15, 2013.

PrEP Facts Clinical trials have shown daily oral Tenofovir to effectively prevent HIV acquisition PrEP must only be prescribed for HIV- patients and patients.

HIV Drug Resistance Surveillance Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO,

The 2013 treatment guidelines and key implementation challenges Martina Penazzato IATT Normative Guidance Advisor HIV Department, WHO (Geneva, Switzerland)

Switch to PI/r monotherapy

WHO perspectives on dolutegravir

Dolutegravir plus Rilpivirine as Maintenance Dual Therapy SWORD-1 and SWORD- 2: Design

Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;

ART 101 Successful HIV treatment usually consists of at least three drugs from two different “classes” of ARV drugs There are now six classes of ARV drugs:

Hospital de Pediatría “Prof. Dr. Juan P. Garrahan”.

Background Results Methods Conclusion

Switch RPV-TDF-FTC from NVP-Based Regimen NEAR-Rwanda Trial

Switching the NRTI Backbone to Tenofovir DF-Emtricitabine TOTEM

Closing the Treatment Gap of Children Living with HIV

Rationale: 2nd Line Regimens in Adults

Martina Penazzato MD, PhD Paediatric lead, HIV Department

Translating Emerging HIV Data Into Clinical Practice

Cepheid Symposium, IAS 23rd July 2018

Existing WHO recommendations for Paediatric ART under review

WHO Technical Reference Group Paediatric HIV/ART CARE

Gaps & obstacles Priorities & Solutions

Switch to LPV/r monotherapy

Anthony D Harries Ministry of Health, Malawi

Switch to ATV/r monotherapy

ARV-trial.com Switch to ATV/r + RAL HARNESS Study 1.

Silvia Bertagnolio, MD HIV Department World Health Organization

Group 4 Gaps & obstacles.

Share your thoughts on this presentation with #IAS2019

The IAS TB/HIV Research Prizes are awarded to:

Presentation transcript:

Group Work Recommendations- what to start Group WHAT 1

Population< 12 months HIV infected Presumptive severe HIV < 11 months InterventionEarly initiation of ARTSame Regimen to be used PMTCT exposed : PI or close monitoring of NNRTI No PMTCT: NNRTI based with same idem

Evidence QualityComments Low HIGH very scarce evidence on efficacy of existing recommendations on NNRTI based regimen Some evidence for lower efficacy of NVP based regimen in NVP exposed vs non exposed infants Very little/no evidence on treatment of non-sick children with NVP based regimen High : acquisition of NNRTI resistance after PMTCT exposure PI based regimen effective in NNRTI resistant patien

Benefits and desired effects DecisionExplanation Assumption/extrapolation: With PI based regimen better chance of efficacy in NVP-exposed kids, esp. in early treatment Protection from development of NRTI-resistance

Risks or undesired effects RiskExplanation ModerateLong-term toxicity unknown Toxicity : Gastro-enteritis PI not available for 2 nd line therapy No FDC – lower adherence Palatability? – lower adherence

Risk/benefits DecisionExplanation StrongBenefits outweigh risks

Feasibility Decision Explanation WEAKConditional on availability Storage, Stability at high temperature level ? (one month up to 25°) Logistic supply Cost

Costs DecisionExplanation ConditionalHigh

Recommendations – What to start ART POPULATION Up to 12 months 1- 4 yrs> 5 START ART PMTCT/NVP exposure : PI-regimen * No PMTCT exposure : NVP-regimen (current recommendations) * In the absence of PI : closed monitoring of 2- NRTI or 3-NRTI +NVP- regimen NVP/EFV+ 2NRTI Strength of recommendation Discuss but strong ! Strong

Key outstanding questions IssueResearch or action required More data on resistance, efficacy and virological response in NVP- based and PI-based early regimen in infancy More data on PK, on adherence, acceptability and NRTI back-bone No data on formulations and their use lack of FDC Look for the best long-term strategy after PMTCT Best sequencing of strategies Operational research +++